Carl L. Gordon
Carl L. Gordon's purchase track record
How the stock did after each of Carl L. Gordon's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/27/2026 | SCTX | $15.00M | pending | pending | — |
| 2/14/2025 | MBX | $2.02M | +7.2% | +41.3% | +5.5% |
| 9/16/2024 | MBX | $12.00M | -11.6% | -59.1% | +0.8% |
| 1/30/2024 | AVBP | $8.00M | -24.9% | 0.0% | +10.4% |
| 1/25/2024 | ACET | $7.50M | -26.7% | -38.9% | +10.3% |
| 6/27/2023 | ACET | $1.83M | -32.9% | -22.1% | +9.0% |
| 11/8/2022 | CMPX | $1.29M | -7.1% | -20.0% | +7.6% |
| 5/6/2022 | CMPX | $618K | +57.4% | +136.7% | -8.6% |
| 11/4/2021 | CMPX | $18.75M | -54.9% | -57.1% | -11.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial. Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Compass Therapeutics faces analyst downgrades after FDA setback. Compass Therapeutics is facing renewed scrutiny following an FDA setback for tovecimig, which H.C. Wainwright described as a risky filing strategy. Several firms, including Citizens, Guggenheim, and Craig-Hallum, lowered their price targets to $4 or $8 while maintaining positive ratings. The stock's RSI is near 20.7, indicating it is currently trading in oversold territory.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MBX Biosciences to Attend Investor Conferences, Analyst Target Raised. MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target. Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
AVBP: First Patient Dosed in Phase 1 Dual-Target ADC Trial. ArriVent BioPharma reported that the first patient has been dosed in its Phase 1 study of the dual‑target antibody‑drug conjugate ARR‑002 for ovarian and endometrial cancer. The trial uses a tetravalent design that targets both MUC16 and NaPi2b. BTIG reaffirmed its rating on the company and kept its $29 price target. The news arrives while the stock trades near recent support and shows an RSI in oversold territory.
Transaction History
| SCTX | ▲ Buy | Open Market | 1,000,000 | $15.0M | 7/27/2026 | View on chart |
| SCTX | ▼ Sell | Other | 348,825 | — | 7/27/2026 | View on chart |
| KROS | ▼ Sell | Other | 140,057 | $2.5M | 11/21/2025 | View on chart |
| KROS | ▼ Sell | Other | 74,465 | $1.3M | 11/21/2025 | View on chart |
| KROS | ▲ Buy | Grant | 5,250 | $0 | 6/4/2025 | View on chart |
| CMPX | ▼ Sell | Open Market | 3,571,428 | $5.7M | 4/9/2025 | View on chart |
| MBX | ▲ Buy | Open Market | 94,100 | $1.0M | 2/18/2025 | View on chart |
| MBX | ▲ Buy | Open Market | 49,070 | $532K | 2/18/2025 | View on chart |
| MBX | ▲ Buy | Open Market | 17,962 | $178K | 2/14/2025 | View on chart |
| MBX | ▲ Buy | Open Market | 29,540 | $291K | 2/14/2025 | View on chart |
| MBX | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 | View on chart |
| MBX | ▼ Sell | Other | 2,658,428 | — | 9/16/2024 | View on chart |
| MBX | ▼ Sell | Other | 403,787 | — | 9/16/2024 | View on chart |
| MBX | ▲ Buy | Open Market | 250,000 | $4.0M | 9/16/2024 | View on chart |
| KROS | ▼ Sell | Open Market | 29,400 | $1.3M | 8/13/2024 | View on chart |
| KROS | ▼ Sell | Open Market | 220,600 | $9.7M | 8/13/2024 | View on chart |
| ACET | ▲ Buy | Grant | 5,900 | $0 | 6/5/2024 | View on chart |
| AVBP | ▼ Sell | Other | 821,827 | — | 1/30/2024 | View on chart |
| AVBP | ▼ Sell | Other | 821,827 | — | 1/30/2024 | View on chart |
| AVBP | ▼ Sell | Other | 469,615 | — | 1/30/2024 | View on chart |
| AVBP | ▼ Sell | Other | 469,615 | — | 1/30/2024 | View on chart |
| AVBP | ▲ Buy | Open Market | 222,222 | $4.0M | 1/30/2024 | View on chart |
| AVBP | ▲ Buy | Open Market | 222,222 | $4.0M | 1/30/2024 | View on chart |
| ACET | ▲ Buy | Open Market | 1,841,100 | $4.4M | 1/25/2024 | View on chart |
| ACET | ▲ Buy | Open Market | 1,041,700 | $2.5M | 1/25/2024 | View on chart |
| ACET | ▲ Buy | Open Market | 242,200 | $581K | 1/25/2024 | View on chart |
| ACET | ▲ Buy | Open Market | 125,000 | $261K | 6/27/2023 | View on chart |
| ACET | ▲ Buy | Open Market | 250,000 | $522K | 6/27/2023 | View on chart |
| ACET | ▲ Buy | Open Market | 442,000 | $924K | 6/27/2023 | View on chart |
| ACET | ▲ Buy | Open Market | 58,000 | $121K | 6/27/2023 | View on chart |
| ACET | ▲ Buy | Grant | 5,900 | $0 | 6/1/2023 | View on chart |
| CMPX | ▲ Buy | Open Market | 402,000 | $1.3M | 11/8/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 30,722 | $76K | 5/13/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 97,094 | $228K | 5/12/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 64,700 | $116K | 5/11/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 24,447 | $39K | 5/10/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 90,712 | $142K | 5/9/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 10,200 | $17K | 5/6/2022 | View on chart |
| ACET | ▲ Buy | Grant | 214,285 | $3.0M | 12/10/2021 | View on chart |
| CMPX | ▲ Buy | Open Market | 3,571,428 | $12.5M | 11/4/2021 | View on chart |
| CMPX | ▲ Buy | Open Market | 1,785,715 | $6.3M | 11/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Cathie Wood's ARKG adds Scribe Therapeutics to its biotech holdings
ARK Genomic Revolution ETF (ARKG) increased its position in Scribe Therapeutics, as reported by Yahoo and Benzinga. The addition places Scribe among four biotech names that the fund has recently loaded up on. The stock also appeared in a list of health‑care shares moving in the pre‑market session. This news brings additional attention to the company while the stock shows modest momentum on the chart.
Cathie Wood's ARKG adds Scribe Therapeutics to its biotech holdings. ARK Genomic Revolution ETF (ARKG) increased its position in Scribe Therapeutics, as reported by Yahoo and Benzinga. The addition places Scribe among four biotech names that the fund has recently loaded up on. The stock also appeared in a list of health‑care shares moving in the pre‑market session. This news brings additional attention to the company while the stock shows modest momentum on the chart.